Travere Therapeutics Inc (NASDAQ: TVTX) on Monday, plunged -8.94% from the previous trading day, before settling in for the closing price of $19.68. Within the past 52 weeks, TVTX’s price has moved between $5.12 and $25.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 13.83% over the past five years. The company achieved an average annual earnings per share of 70.49%. With a float of $87.41 million, this company’s outstanding shares have now reached $87.45 million.
Let’s look at the performance matrix of the company that is accounted for 385 employees. In terms of profitability, gross margin is 92.24%, operating margin of -138.0%, and the pretax margin is -137.45%.
Travere Therapeutics Inc (TVTX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Travere Therapeutics Inc is 1.50%, while institutional ownership is 109.22%. The most recent insider transaction that took place on Feb 12 ’25, was worth 122,356. In this transaction SENIOR VICE PRESIDENT, R&D of this company sold 5,200 shares at a rate of $23.53, taking the stock ownership to the 98,519 shares. Before that another transaction happened on Feb 12 ’25, when Company’s SVP, GC & CORPORATE SECRETARY sold 8,000 for $23.53, making the entire transaction worth $188,240. This insider now owns 89,482 shares in total.
Travere Therapeutics Inc (TVTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 70.49% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Travere Therapeutics Inc (TVTX) is currently performing well based on its current performance indicators. A quick ratio of 2.04 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.82.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.10, a number that is poised to hit -0.55 in the next quarter and is forecasted to reach 0.84 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Travere Therapeutics Inc (NASDAQ: TVTX) saw its 5-day average volume 1.49 million, a negative change from its year-to-date volume of 1.64 million. As of the previous 9 days, the stock’s Stochastic %D was 22.88%. Additionally, its Average True Range was 1.12.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 15.31%, which indicates a significant increase from 11.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 66.41% in the past 14 days, which was higher than the 57.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.66, while its 200-day Moving Average is $15.54. Nevertheless, the first resistance level for the watch stands at $18.96 in the near term. At $20.00, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.76. If the price goes on to break the first support level at $17.17, it is likely to go to the next support level at $16.41. Assuming the price breaks the second support level, the third support level stands at $15.37.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
Market capitalization of the company is 1.59 billion based on 88,740K outstanding shares. Right now, sales total 233,180 K and income totals -321,550 K. The company made 74,790 K in profit during its latest quarter, and -60,260 K in sales during its previous quarter.
